Terms and Conditions of the ABSA Warrant (incorporated by reference to Exhibit A of the Form of Securities Purchase Agreement filed as Exhibit 10.1 hereto)

This securities purchase agreement (the “Agreement”) is made as of the date set forth below between DBV Technologies S.A., a société anonyme organized under the laws of the French Republic, with a share capital of €10,285,626.30 consisting of 102,856,263 shares of €0.10 nominal value each and a registered office at 107 avenue de la République, 92320 Chatillon, France, registered with the Commerce and Companies Registry (Registre du commerce et des sociétés) of Nanterre under the number 441 772 522, the ordinary shares of which are listed on the regulated market of Euronext Paris (“Euronext”) – ISIN FR0010417345 and on the Nasdaq Capital Market (“Nasdaq”) in the form of American Depositary Shares (the “Company”), and the Subscriber.

Pursuant to the 24^th resolution adopted by the combined general meeting of shareholders on May 16, 2024, the decisions adopted by the Company’s board of directors dated March 27, 2025 and the decisions of the Chief Executive Officer (Directeur Général) dated March 27, 2025, the Company has decided to issue, without shareholders’ preferential subscription rights, to a specific category of beneficiaries, 34,090,004 shares with warrants attached (the “ABSAs”) and 71,005,656 pre-funded warrants to purchase up to 71,005,656 shares with warrants attached (the “PFW-BS-PFWs”).

The New Shares, [the First Pre-Funded Warrants, the BS Warrants, the Second Pre-Funded Warrants, the new ordinary shares issuable upon exercise of the First Pre-Funded Warrants (collectively, the “First PFW Shares”), the new ordinary shares issuable upon exercise of the Second Pre-Funded Warrants (collectively, the “Second PFW Shares”)], the ABSA Warrants, and the ABSA Warrant Shares collectively are referred to herein as the “Securities”.

The Company and the Subscriber agree that the Subscriber will subscribe for a number of [ABSAs]/[PFW-BS-PFWs] set forth below from the Company and, in turn, upon receipt of the aggregate amount set forth above, on the Closing Date (as defined in Annex I-A), the Company will issue such [ABSAs]/[PFW-BS-PFWs] to the Subscriber. The [ABSAs]/[PFW-BS-PFWs] shall be subscribed for pursuant to, and the manner of settlement shall be as set forth in, the Terms and

Annex I-C to this Agreement sets forth the number of ABSAs or PFW-BS-PFWs, as applicable, to be acquired by the Subscriber and each Other Subscriber as of the Closing Date.

The Company and the Subscriber agree that the Subscriber will subscribe, and the Company will issue to the Subscriber, the [ABSAs]/[PFW-BS-PFWs] as follows:

Which shall include, for the avoidance of doubt, €0.2028 (corresponding to USD 0.21875) per Warrant in order to comply with Nasdaq rules.

Annex I-A:  Terms and Conditions for the Subscription of the [ABSAs]/[PFW-BS-PFWs]

Annex I-B: Representations and Warranties of the Company

Annex I-C: Number of ABSAs or PFW-BS-PFWs, as applicable, to be acquired by the Subscribers

Exhibit A  Terms and Conditions of the ABSA Warrants

[Exhibit B  Terms and Conditions of the First Pre-Funded Warrants

Exhibit C  Terms and Conditions of the BS Warrants

Exhibit D   Terms and Conditions of the Second Pre-Funded Warrants]

Exhibit E   Form of Notice

Exhibit F   Registration Rights Agreement

Exhibit G   Subscriber Questionnaire

Authorization and Issue of the [ABSAs]/[PFW-BS-PFWs]

Agreement to Issue and Subscribe for the [ABSAs]/[PFW-BS-PFWs] – Placements Agents

The [ABSAs]/[PFW-BS-PFWs] are being or will be offered to a limited number of investors who have represented that they belong to the group of specified categories of investors under the provisions of Article L.225-138 of the French Commercial Code and that they are “accredited investors” within the meaning of Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”), who are either (i) “qualified institutional buyers” within the meaning of Rule 144A (“Rule 144A”) under the Securities Act or (ii) institutional “accredited investors” within the meaning of Rule 501(a) under the Securities Act, in each case pursuant to the exemption from registration under Regulation D of the Securities Act, and, if the investors are located in the European Union (including in France), that they qualify as “qualified investors” within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended.

At the Closing Date (as defined below), the Company will issue and sell to the Subscriber, and the Subscriber will subscribe, upon the terms and conditions set forth herein and in consideration for the payment of the Subscriber Aggregated Subscription Price therefor set forth in the Agreement, to the number of [ABSAs]/[PFW-BS-PFWs] set forth in the signature page of this Agreement to which these Terms and Conditions for Subscription of [ABSAs]/[PFW-BS-PFWs] are attached as Annex I-A, in consideration for the payment of the Subscriber Aggregated Subscription Price therefor set forth in the Agreement.

The Subscriber acknowledges that the Company intends to pay LifeSci Capital LLC and Van Lanschot Kempen N.V. (the “Placement Agents”) a fee in connection with the Transaction, pursuant to the engagement letters entered into by the Company with each Placement Agent. Furthermore, the Subscriber acknowledges that Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Advisor”) is acting as a financial advisor to the Company in connection with the Transaction and will receive a fee in connection with services provided by it pursuant to an engagement letter with the Company.

All representations and warranties, covenants and agreements made or given by the Company to the Subscriber herein, and specifically as made or given in this Annex I-A, are also irrevocably made and given for the benefit of the Placement Agents and the Advisor, and the Placement Agents and the Advisor are entitled to rely on the same in connection with the Transaction.

The Company will enter into this same form of securities purchase agreement with the same economic terms and obligations with other investors (the “Other Subscribers”) in connection with the Transaction and will complete the issuance of ABSAs [and PFW-BS-PFWs] to such Other Subscribers on the terms set forth herein (the “Other Agreements”). No Other Agreement (or other agreements or understandings (including side letters) entered into in connection therewith or in connection with the issuance of ABSAs [and PFW-BS-PFWs]) shall have been amended, modified or waived in any manner related to the economic terms and conditions that benefits any Other Subscriber unless the Subscriber shall have been offered in writing the same economic benefits (other than terms particular to the legal or regulatory requirements of such Other Subscriber or its affiliates or related persons). The Subscriber and the Other Subscribers are hereinafter sometimes collectively referred to as the “Subscribers”.

Closings and Delivery of the [ABSAs]/[PFW-BS-PFWs] and Funds

Closing

Conditions to Closing

Conditions to the Company’s Obligations

Conditions to Each Subscriber’s Obligations

Conditions to Either Party’s Performance

Delivery of the funds

Delivery of [ABSAs]/[PFW-BS-PFWs]

Representations, Warranties and Covenants of the Subscriber

The Subscriber represents and warrants to, and covenants with, the Company, each Placement Agent and the Advisor that:

The Subscriber:

is either, as provided by the 24^th resolution adopted by the combined general meeting of shareholders of the Company of May 16, 2024, a (i) natural person or legal entity, including company, trust, investment fund or other investment vehicle, regardless of its form, under French or foreign law, investing on a regular basis in the pharmaceutical, biotechnological or medical technology sectors, and/or (ii) French or foreign company, institution or entity of any form, carrying out a significant portion of its business in the pharmaceutical, chemical, medical devices or technology sectors or conducting research in these areas; and/or (iii) French or foreign investment service provider, or any foreign establishment with equivalent status, likely to guarantee the completion of an issue intended to be placed with the persons referred to in (i) and/or (ii) above or in connection with the implementation of an equity or bond financing line and, in this context, to subscribe for the securities issued; and

is an “accredited investor” as defined in Rule 501 of Regulation D under the Securities Act, who is either (i) a “qualified institutional buyer” as defined in Rule 144A under the Securities Act or (ii) an institutional “accredited investor” within the meaning of Rule 501(a) of Regulation D under the Securities Act, and has executed and delivered to the Company a questionnaire in substantially the form attached hereto as Exhibit [G], which the Subscriber represents and warrants is true, correct and complete; and

if the Subscriber is located in the European Union (including in France), is a “qualified investor” within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended;

The Subscriber is knowledgeable, sophisticated and experienced in financial, business and international investment matters as to be capable of evaluating the merits and risks of purchasing the [ABSAs]/[PFW-BS-PFWs] and the Subscriber is experienced in investing in securities of this nature. The Subscriber has relied on its own independent examination and due diligence of the Company and its subsidiaries, the terms of the Transaction, the representations, warranties and covenants of the Company as disclosed below in Section 5, and the merits and risks involved. The Subscriber has: (i) made its own assessment, to its satisfaction, concerning legal, regulatory, tax, business and financial considerations in connection with the Transaction, (ii) had access to all publicly available information concerning the Company and its subsidiaries that it considers necessary or appropriate and sufficient in making an investment decision, (iii) reviewed such information as it believes are necessary or appropriate in connection with its purchase of the [ABSAs]/[PFW-BS-PFWs] and (iv) made its investment decision based solely upon its own judgement, due diligence and analysis, and the representations, warranties and covenants of the Company.

The Subscriber is acquiring its number of [ABSAs]/[PFW-BS-PFWs] set forth in the signature page of this Agreement for its own account for investment only and with no present intention of distributing any of such [ABSAs]/[PFW-BS-PFWs], or any arrangement or understanding with any other persons regarding the distribution of such [ABSAs]/[PFW-BS-PFWs]; provided however, that the Subscriber does not agree, or make any representation or warranty, to hold the [ABSAs]/[PFW-BS-PFWs], for any minimum or other specified term.

The Subscriber will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the [ABSAs]/[PFW-BS-PFWs], except in compliance with the laws of France regarding the offering of securities, Regulation (EU) No 596/2014 of 16 April 2014 on market abuse, the Securities Act, and applicable state securities laws and the respective rules and regulations promulgated thereunder.

The Subscriber’s information on the signature page hereto may be used in connection with the admission to trading and listing of the New Shares on Euronext and with the registration of the Securities under the Securities Act pursuant to the Registration Rights Agreement and the information thereon is true and correct as of the date hereof and will be true and correct as of the Closing Date.

The Subscriber will notify the Company promptly if any of the representations, warranties or undertakings set forth in Section 4.1(a) through (e) become no longer true until the Closing Date.

The Subscriber has, in connection with its decision to purchase the number of [ABSAs]/[PFW-BS-PFWs] set forth in the signature page of this Agreement, relied only upon (i) information made available by the Company or its affiliates, directors, officers, employees, financial advisors, and agents (collectively, its “Representatives”) to the Subscriber, including without limitation, the representations and warranties contained in Annex I-B attached hereto, (ii) the universal registration document (document d’enregistrement universel) filed with the Autorité des marchés financiers (“AMF”) on March 8, 2024 under number D.24-0086 (the “Universal Registration Document”), (iii) the Company’s half-year financial report as of June 30, 2024, published on the Company’s website on July 30, 2024 (the “2024 Half-Year Financial Report”), (iv) a press release presenting the unaudited 2024 fiscal year financial results of the Company as of December 31, 2024, published on the Company’s website on March 24, 2025 (the “Unaudited 2024 Financial Results Press Release”), and (v) the SEC Filings (as defined below) (the SEC Filings together with the Universal Registration Document, the 2024 Half-Year Financial Report and the Unaudited 2024 Financial Results, the “Disclosure Materials”). The Subscriber acknowledges that certain Disclosure Materials, including those available on the Company’s website or elsewhere in the public domain, have been published only in French. The Subscriber has carefully considered the potential risks relating to the Company and a purchase of the [ABSAs]/[PFW-BS-PFWs], and fully understands that the Securities are speculative investments which involve a high degree of risk of loss of its entire investment.

The Subscriber acknowledges that it is not relying upon, and has not relied upon, any statement, representation or warranty made by the Placement Agents or Advisor, any of their respective affiliates or any of their respective control persons, officers, directors and employees in making its investment or decision to invest in the Company. The Subscriber agrees that no Placement Agent or Advisor shall be liable to the Subscriber for any action heretofore or hereafter taken or omitted to be taken by any of them or have any liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by the Subscriber, the Company or any other person or entity), whether in contract, tort or otherwise, to the Subscriber, or to any person claiming through the Subscriber, in respect of the transactions contemplated by this Agreement. The Subscriber hereby acknowledges and agrees that (a) each Placement Agent is acting solely as the Company’s placement agent in connection with the transactions contemplated by this Agreement and neither the Placement Agent nor the Advisor is acting as an underwriter or in any other capacity and the Placement Agents and Advisor are not and shall not be construed as a fiduciary for the Subscriber, the Company or any other person or entity in connection with the transactions contemplated by this Agreement, (b) no Placement Agent or Advisor has made or will make any representation or warranty, whether express or implied, of any kind or character and has not provided any advice or recommendation in connection with the transactions contemplated by this Agreement, and (c) no Placement Agent or Advisor will have any responsibility with respect to (i) any representations, warranties or agreements made by any person or entity under or in connection with the transactions contemplated by this Agreement or any of the documents furnished pursuant thereto or in connection therewith, or the execution, legality, validity or enforceability (with respect to any person) or any thereof, or (ii) the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company or the transactions contemplated by this Agreement. Neither the Placement Agents, the Advisor nor any of their respective affiliates have made or make any representation as to the quality or value of [ABSAs]/[PFW-BS-PFWs] and such Placement Agents, the Advisor and any of their respective affiliates may have acquired non-public information with respect to the Company which such Subscriber agrees need not be provided to it.

The Subscriber is able to bear the economic risk of loss of such investment, including the complete loss of such investment. The Subscriber further represents that it understands the limitations on transfer and restrictions on sales and other dispositions set forth in this Agreement.

The Subscriber is not purchasing the [ABSAs]/[PFW-BS-PFWs], as a result of any advertisement, article, notice or other communication regarding the [ABSAs]/[PFW-BS-PFWs] published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the Subscriber’s knowledge, any other general solicitation or general advertisement.

The Subscriber further represents, warrants, acknowledges and agrees that, if the Subscriber is acting on behalf of investment funds or other legal entities managed or advised by it, the representations made under Section 4 shall also apply to each such fund or legal entity and the Subscriber shall further ensure compliance thereof by each such fund or entity in connection with the initial distribution of the [ABSAs]/[PFW-BS-PFWs].

The Subscriber acknowledges that there may be certain consequences under U.S. and other tax laws resulting from an investment in the [ABSAs]/[PFW-BS-PFWs] and will make such investigations and consult such tax and other advisors with respect thereto as they deem appropriate. The Subscriber understands that nothing in this Agreement or any other materials presented to it in connection with the subscription and sale of the [ABSAs]/[PFW-BS-PFWs] constitutes legal, tax or investment advice.

The Subscriber acknowledges that, prior to the execution and delivery of this Agreement to the Company, the Subscriber has had adequate time to review the Disclosure Materials prior to making its decision to purchase the [ABSAs]/[PFW-BS-PFWs], and has had a full opportunity to ask questions of and receive answers from the Company or any person or persons acting on behalf of the Company concerning the terms and conditions of an investment in the Company. The Subscriber further acknowledges that any such information consisting of financial estimates, projected financial information and other forward-looking information provided by the Company or its affiliates or representatives is based on a number of assumptions and estimates that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies which are beyond the control of the Company, and that it is understood that such projections, as to future events, are not to be viewed as facts, that actual results during the period or periods covered by any such projections may differ significantly from the projected results and that such difference may be material and that such projections are not a guarantee of financial performance.

The Subscriber acknowledges, represents and agrees that no action has been or will be taken in any jurisdiction, including the Republic of France, which would permit a public offering of the [ABSAs]/[PFW-BS-PFWs] (other than to the Subscriber), or possession or distribution of offering materials in connection with the issue of the [ABSAs]/[PFW-BS-PFWs] in any jurisdiction where action for that purpose is required. The Subscriber will comply with all applicable laws and regulations in each jurisdiction in which it subscribes, offers, sells or delivers [ABSAs]/[PFW-BS-PFWs], or has in its possession or distributes any offering material, in all cases at its own expense.

The Subscriber further represents and warrants to, and covenants with, the Company that (a) it has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and performance of this Agreement, and (b) this Agreement constitutes a valid and binding obligation of the Subscriber enforceable against it in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).

Neither the execution of this Agreement by the Subscriber nor the subscription of the [ABSAs]/[PFW-BS-PFWs] by the Subscriber violates or will violate (i) any provision of the articles of association (or equivalent constituent documents) of the Subscriber, (ii) any material applicable law or material regulation binding upon the Subscriber or its assets, (iii) any judgment, order or decree of any governmental body, agency or court having jurisdiction over the Subscriber or any of its assets, (iv) the rules of any stock exchange as they apply to the Subscriber, and (v), any other material agreements to which the Subscriber is a party, in each case, with respect to clauses (i) – (v) of this Section 4.7, except to the extent that such violation would not reasonably be expected to materially impair or delay the Subscriber’s ability to perform its obligations under this Agreement.

The Subscriber acknowledges, covenants and agrees that (a) the issuance and sale of the [ABSAs]/[PFW-BS-PFWs] has not been registered under the Securities Act or registered or qualified under any state securities law, in reliance on exemptions therefrom, and therefore the [ABSAs]/[PFW-BS-PFWs], and all securities included therein or into which the [ABSAs]/[PFW-BS-PFWs] are convertible or exercisable, will be “restricted securities” within the meaning of Rule 144 under the Securities Act and (b) all such restricted securities described in clause (a) hereof cannot be resold or otherwise transferred unless

The Subscriber represents and warrants that the Subscriber Aggregated Subscription Price will not be derived from sources prohibited under programs administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury and that the operations of the Subscriber is in compliance with applicable financial record keeping and reporting requirements of the anti-money laundering laws and regulations of United States.

The Subscriber does not act “in concert” (within the meaning of Article L.233-10 of the French Commercial Code) with any Company’s shareholder or third party.

The Subscriber represents and warrants that it has not entered into any short sales (as defined in Rule 200 of Regulation SHO under the Exchange Act of 1934, as amended (the “Exchange Act”)), with respect to the Company’s securities since the Subscriber became aware of the Transaction and ending immediately prior to the execution of this Agreement. Notwithstanding the foregoing, in the case of a Subscriber that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of Subscriber’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of Subscriber’s assets, the representation set forth in the first sentence of this Section 4.11 shall only apply with respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the [ABSAs]/[PFW-BS-PFWs].

The Subscriber’s offices in which the Subscriber’s investment decision with respect to the [ABSAs]/[PFW-BS-PFWs], was made are in the jurisdiction set forth in Section 8(b) of this Agreement.

The Subscriber has not taken any of the actions set forth in, and is not subject to, the disqualification provisions of Rule 506(d)(1) of the Securities Act.

The Subscriber undertakes that:

It will comply with any notification requirements to the AMF with respect to the subscription of the Securities (notably disclosure of threshold crossing and intent), which may be required to be made under any applicable law and the Company’s by-laws as well as any requirement in relation with foreign direct investment in France pursuant to the French Monetary and Financial Code and the French Decree (décret) no. 2020-892 of July 22, 2020 as lastly amended by the French Decree (décret) no. 2023-1293 of December 28, 2023 and ministry order (arrêté) of December 28, 2023, as amended from time to time and implementing regulation.

It will sign and execute such documents and take such actions as are necessary for the consummation of the subscription of the Securities to the Subscriber hereunder, pursuant to the terms and conditions of this Agreement.

Subject to a special report from the Company’s auditors without any qualification, it will vote in favor of the resolutions at a Company’s general meeting to be convened to approve the entry into the same form of securities purchase agreement with any Other Subscriber that would be qualified as a regulated agreement (convention réglementée) pursuant to Article L. 225-38 of the French Commercial Code.

Representations, Warranties and Covenants of the Company

The Company represents and warrants to, and covenants with, the Subscriber that:

(A) The shareholders of the Company, at the combined general meeting of shareholders of May 16, 2024 waived their preferential subscription rights in favor of certain investors who are: (i) natural person(s) or legal entity(ies), including companies, trusts, investment funds or other investment vehicle(s), regardless of their form, under French or foreign law, investing on a regular basis in the pharmaceutical, biotechnological or medical technology sector, and/or (ii) French or foreign companies, institutions or entities of any form, carrying out a significant portion of their business in pharmaceutical, chemical, medical devices or technology sectors or conducting research in these areas; and/or (iii) French or foreign investment service provider(s), or any foreign establishment(s) with equivalent status, likely to guarantee the completion of an issue intended to be placed with the persons referred to in (i) and/or (ii) above or in connection with the implementation of an equity or bond financing line and, in this context, to subscribe for the securities issued, and (B) that, subject to Subscriber’s representations in Section 4.1(a) of this Agreement being true, the Subscriber falls within said category.

The Company shall take all necessary action to cause the [New Shares]/[the First PFW Shares], upon the exercise of the ABSA Warrants, the ABSA Warrant Shares and upon the exercise of the Second Pre-Funded Warrants, the Second PFW Shares to be listed on Euronext and will cause the [New Shares]/[the First PFW Shares], the ABSA Warrant Shares [and the Second PFW Shares] to be approved for admission to trading and listed on Euronext [on or about the Closing Date for the New Shares]/[at the time of the issuance of the First PFW Shares and Second PFW Shares, as applicable] and at the time of the issuance of the ABSA Warrant Shares in accordance with the Terms and Conditions of the ABSA Warrants for the ABSA Warrant Shares [and the Terms and Conditions of the Second Pre-Funded Warrants for the Second PFW Shares]. The [ABSA Warrants / First Pre-Funded Warrants, BS Warrants and Second Pre-Funded Warrants] are not listed on Euronext or on any other stock exchange but are admitted to clearing on Euroclear France. The Company hereby agrees to use its best efforts to maintain the listing or quotation of the American Depositary Shares of the Company (“ADSs”) on the Principal Market (as defined below) on which the ordinary shares are currently listed.

As MPM Capital shall have the right to propose a candidate for one (1) director of the Company, the Company undertakes to have such proposed candidate put forward for consideration for appointment by the Company’s shareholders.

Until the ABSA Warrants are no longer outstanding, the Company will notify, as provided in Section 8 of this Agreement, the Subscribers promptly after publication by the Company of a press release announcing (i) that the ongoing VITESSE trial of VIASKIN peanut in 4-7 year old (NCT05741476) met the primary endpoint defined in the VITESSE study protocol and (ii) any suspension of the ability to exercise the ABSA Warrants in accordance with the Terms and Conditions of the ABSA Warrants.

To the best of its knowledge, the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the Transaction, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale have taken any of the actions set forth in, and are not subject to, the disqualification provisions of Rule 506(d)(1) of the Securities Act.

The representation and warranties of the Company attached hereto as Annex I-B may be relied upon by the Subscriber and the Subscriber shall be a beneficiary of such representations and warranties and shall be deemed to have accepted the benefit of such representations and warranties.

Other Covenants

The Subscriber covenants that the [ABSAs]/[PFW-BS-PFWs] will only be sold, offered for sale, pledged, loaned, or otherwise disposed of pursuant to an effective registration statement under, and in compliance with the requirements of, the Securities Act or pursuant to an available exemption from the registration requirements of the Securities Act, and in compliance with any applicable state securities laws. In connection with any transfer of [New Shares]/[First Pre-Funded Warrants] other than pursuant to an effective registration statement or Rule 144, the Company may require the Subscriber to provide to the Company an opinion of counsel selected by the Subscriber, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration under the Securities Act.

The Subscriber shall take no action to become a group such that any transactions contemplated by this Agreement would require shareholder approval prior to Closing.

The Subscriber shall not issue any press releases or any other public statements with respect to the Transaction contemplated hereby except as may be reviewed and approved by the Company; provided, however, that the Company shall be entitled, without the prior approval of any Subscribers, to make any press release or other public disclosure with respect to the Transaction contemplated hereby and publicly disclose therein the name of any Subscribers and any affiliate of any Subscribers to the extent necessary to comply with the requirements of the AMF regulation and guidelines.

By 9:00 a.m. (Paris time) on the Business Day immediately following the date this Agreement is executed, the Company shall issue a press release disclosing all material terms of the transactions contemplated by this Agreement (the “Press Release”). From and after the issuance of the Press Release, no Subscriber shall be in possession of any material nonpublic information and/or inside information received from the Company, its subsidiaries or any of their respective officers, directors, employees or agents (including the Placement Agents and the Advisor). In addition, the Company will make such other filings and notices in the manner and time required by the SEC, the AMF or Euronext. The Company shall not, and shall cause each of its officers, directors, employees and agents not to, provide any Subscriber with any such material nonpublic information or insider information regarding the Company from and after the release of the Press Release without the express prior written consent of such Subscriber. Except as may otherwise be agreed with a given Subscriber, to the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or its subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that the Subscriber shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The “Transaction Documents” refers to this Agreement and the Registration Rights Agreement.

The Company shall timely file a Form D with respect to the [ABSAs]/[PFW-BS-PFWs] as required under Regulation D of the Securities Act. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the [ABSAs]/[PFW-BS-PFWs] for, sale to the Subscriber at the Closing Date under applicable securities or “blue sky” laws of the states of the United States.

Survival of Representations, Warranties and Agreements

Notices

if to the Company, to:

if to the Subscriber, to:

Changes

Headings

Severability

Governing Law and Jurisdiction

Expenses

Fees and Stamp Taxes and ADS Conversion Assistance

Execution of Agreement

Termination

there has been any material breach of, or any event rendering untrue or incorrect, in any material respect, any of the representations and warranties contained in Section 5 or any failure to perform any of the Company’s covenants, undertakings or agreements in this Agreement;

any of the conditions specified in Section 3.2(b) or (c) has not been satisfied or waived by the Subscribers;

there shall have been, since the date of this Agreement any material suspension or material limitation of trading on, or by, as the case may be, any of Euronext or the Nasdaq or any setting of minimum prices for trading on any such exchange, by any such exchange or by any other governmental authority having jurisdiction, which makes it, in the reasonable judgment of the Subscriber and after good faith consultation with the Company in advance, impracticable or impossible to proceed with the Transaction or the issue, sale or delivery of the [ABSAs]/[PFW-BS-PFWs], materially on the terms and in the manner contemplated in this Agreement.

Waiver of Conflicts

Good Standing of the Company. The Company is duly constituted as a French public limited company (société anonyme) with a board of directors and registered with the Trade and Companies Registry of Nanterre under the unique identification number of 441 772 522. The Company exists validly, operates in all material respects in accordance with the laws and regulations that apply to it and has made all the filings, statements and registrations required by the competent authorities for the purpose of its activities. Each member of the board of directors (Conseil d’administration), the Chairman of the board of directors (Président du Conseil d’administration) and the Chief Executive Officer (Directeur Général) have been lawfully appointed or elected and are validly in office in accordance with the law and, perform their respective duties in compliance with French law and the Company’s by-laws (statuts) and internal regulations. The Subsidiary (as defined below) has been duly constituted under the laws of the State of Delaware. The Company and the Subsidiary are fully empowered to hold and use their assets.

Good Standing of Subsidiaries. DBV Technologies Inc., a Delaware corporation (the “Subsidiary”) is the Company’s only significant subsidiary (as defined under Rule 1-02 of Regulation S-X). Each of the Company and the Subsidiary has been duly organized and is validly existing as a corporation in good standing under the laws of the jurisdiction in which it is chartered or organized (to the extent the concept of “good standing” or such equivalent concept exists under the laws of such jurisdiction), with full corporate power and authority to own or lease, as the case may be, and to operate its properties and conduct its business as described in the Disclosure Materials, and is duly qualified to do business as a foreign corporation and is in good standing under the laws of each jurisdiction which requires such qualification, except where the failure to be so qualified or in good standing would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”) (to the extent the concepts of “due qualification” and/or “good standing” or such equivalent concepts exists under the laws of such jurisdiction). With respect to the Company and to the Subsidiary (a) no application to enter into a safeguard procedure (procédure de sauvegarde) has been made, (b) no application to enter into an accelerated safeguard procedure (procédure de

Financial Statements. The audited consolidated historical financial statements, the unaudited condensed financial statements as of and for the six-months ended June 30, 2024 and schedules of the Company and its consolidated subsidiaries included or incorporated by reference in the Disclosure Materials present fairly in all material respects the financial condition, results of operations, changes in shareholder’s equity and cash flows of the Company as of the dates and for the periods indicated, comply as to form in all material respects with the applicable accounting requirements of the Securities Act and French laws and regulations, and have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved (except as otherwise noted therein). Such financial statements as of and for the six-months ended June 30, 2024 and the years ended December 31, 2023, 2022 and 2021 are in accordance with IFRS within the meaning of EC Regulation No. 1606/2002 of the European Parliament and of the Council of 19 July 2002 as adopted from time to time by the European Commission in accordance with that Regulation and its interpretations promulgated by the IASB applied on a consistent basis throughout the periods involved (except as noted therein).

Independent Accountants. KPMG S.A. and Deloitte & Associés, who have certified certain financial statements of the Company and its consolidated subsidiaries and delivered their report with respect to the unaudited and audited consolidated financial statements and schedules included directly or incorporated by reference in the Disclosure Materials are independent public accountants with respect to the Company within the meaning of the Securities Act and the applicable published rules and regulations thereunder and as required by the AMF General Regulations and under the professional rules of the “Compagnie Nationale des Commissaires aux Comptes.”

Authorization of the Transaction. The issuance of the [ABSAs]/[PFW-BS-PFWs] has been duly authorized by the Company pursuant to the 24^th resolution adopted by the combined general meeting of shareholders of the Company on May 16, 2024 and the appropriate decisions of the board of directors of the Company dated March 27, 2025 and of the Chief Executive Officer (Directeur Général) dated March 27, 2025, and all ceilings applicable to these authorizations have been respected. Upon (i) payment of the aggregate subscription amounts for the ABSAs [and PFW-BS-PFWs] by all Subscribers in the manner contemplated by this Agreement and (ii) issuance of the depositary certificate (certificat du dépositaire) for the New Shares, the [ABSAs]/[PFW-BS-PFWs] will be duly and validly issued and fully paid. The shareholders of the Company have no preemptive or other rights to acquire the [ABSAs]/[PFW-BS-PFWs] other than preemptive rights (droits préférentiels de souscription) arising pursuant to the French Commercial Code which were validly waived in respect of such [ABSAs]/[PFW-BS-PFWs] by the above-mentioned resolution and there are no restrictions on transfers of the [ABSAs]/[PFW-BS-PFWs] under the laws of France or the statuts of the Company and at the time the [ABSAs]/[PFW-BS-PFWs] are issued and delivered to the Subscriber they will be free and clear from any other claim, lien, encumbrance, security interest, defect or right of any third party.

Capitalization. The Company’s share capital is as disclosed in the Disclosure Materials; the ordinary shares composing the share capital of the Company and any outstanding ADSs as at the date hereof have been duly and validly authorized and issued and are fully paid, non-assessable and freely negotiable and have been issued in compliance with French law and, to the extent applicable, all United States federal, state and local securities laws; the holders of outstanding ordinary shares are not entitled to preemptive rights (droit préférentiel de souscription), priority rights (délai de priorité) or other similar

French Disclosure. All information and other disclosure materials made publicly available by the Company were, as of the date they were made publicly available, true, complete and accurate in all material respects, and complied with the requirements of applicable French law, including French securities law, the AMF regulation and guidelines, the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended.

SEC Filings. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (the “SEC Filings”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Filings prior to the expiration of any such extension. As of their respective dates, such SEC Filings complied as to form in all material respects with the requirements of the Securities Act or Exchange Act, as applicable, and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. There are no material outstanding or unresolved comments in comment letters from the staff of the Securities and Exchange Commission (the “Commission”) with respect to any of the SEC Filings as of the date hereof.

Authorization of this Agreement. This Agreement has been duly authorized, executed and delivered by the Company and constitutes a valid and legally binding agreement of the Company, enforceable against the Company in accordance with its terms, subject, as to enforceability, to bankruptcy, insolvency, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights and to general equity principles. The Company has full power and capacity to enter into this Agreement, the execution and the completion of the obligations described in this Agreement; all the notices, authorizations and approvals necessary to proceed with the valid issuance of the [ABSAs]/[PFW-BS-PFWs] (and, for the sake of clarity, [the First Pre-Funded Warrants, the BS Warrants, the Second Pre-Funded Warrants and] the ABSA Warrants), and those necessary for execution by the Company of its obligations hereunder have been duly obtained and will remain in force on the Closing Date.

Corporate Purpose. The sale of the [ABSAs]/[PFW-BS-PFWs] pursuant to this Agreement are in the Company’s corporate interest and serving the Company’s corporate purpose (objet social) as set forth in the Company’s by-laws (statuts) or other constitutional documents and are on an arm’s-length basis between the Company, on the one hand, and the Placement Agents and any of their respective affiliates through which they may be acting, on the other.

Absence of Violations, Defaults and Conflicts. Neither the Company nor the Subsidiary is in violation or default of (i) any provision of its charter or bylaws, (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which it is a party or bound or to which its property is subject, or (iii) any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or the Subsidiary or any of its properties, as applicable, except in the case of clauses (ii) and (iii), for such violation or default as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Neither the issuance and sale of the Securities nor the consummation of any other of the transactions herein contemplated nor the fulfillment of the terms hereof will conflict with, result in a breach or violation of, or imposition of any lien, charge or encumbrance upon any property or assets of the Company or the Subsidiary pursuant to, (A) the charter or by-laws of the Company or the Subsidiary, (B) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company or the Subsidiary is a party or bound or to which its or their property is subject, or (C) any statute, law, rule, regulation, judgment, order or decree applicable to the Company or the Subsidiary of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or the Subsidiary or any of its or their properties, except in the case of clause (B) and (C), as would not reasonably be expected to have a Material Adverse Effect on the Company’s ability to consummate the transactions contemplated hereby.

Absence of Labor Dispute. No labor problem or dispute with the employees of the Company or the Subsidiary exists or, to the Company’s knowledge, is threatened or imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or the Subsidiary’s principal suppliers, contractors or customers, that would reasonably be expected to have a Material Adverse Effect, except as set forth in or contemplated in the Disclosure Materials.

Absence of Proceedings. No action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or the Subsidiary or its or their property is pending or, to the knowledge of the Company, threatened that (i) would reasonably be expected to have a Material Adverse Effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby or (ii) would reasonably be expected to have a Material Adverse Effect, except as set forth in or incorporated by reference into the Disclosure Materials.

Absence of Further Requirements. Excluding any filing required to be made under applicable law or regulation by the Company with the AMF in France, which has been made or will be made in a timely manner and except as set forth in this Agreement, no consent, approval, authorization, filing with or order of any court or governmental agency or body is required in connection with the performance by the Company of its obligations hereunder in respect of the Transaction or the issuance of the [ABSAs]/[PFW-BS-PFWs], except such as have already been obtained, and such as may be required under the Securities Act or the blue sky laws of any jurisdiction.

Possession of Licenses and Permits. The Company and the Subsidiary possess all licenses, certificates, permits and other authorizations issued by all applicable authorities necessary to conduct their respective businesses, except in each case, the lack of which would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and neither the Company nor the Subsidiary have received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect except as set forth in or contemplated in the Disclosure Materials.

Compliance with Regulatory Laws. Except as described in the Disclosure Materials, as applicable, the Company and the Subsidiary (i) are and at all times have been in compliance with all applicable statutes, rules and regulations in the United States or any other jurisdiction applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product candidate under development, manufactured or distributed by the Company, including, without limitation, the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.), the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the exclusion law (42 U.S.C. § 1320a-7), the statutes, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the regulations promulgated pursuant to such laws, including, without limitation, the collection and reporting requirements, and the processing of any applicable rebate, chargeback or adjustment, under applicable rules and regulations relating to the VA Federal Supply Schedule (38 U.S.C. § 8126) or under any U.S. Department of Veterans Affairs agreement, and any successor government programs, and comparable state laws, regulations relating to Good Clinical Practices and Good Laboratory Practices and all other local, state, federal, national, supranational and foreign health care laws, manual provisions, policies and administrative guidance, in each case relating to the regulation of the Company or the Subsidiary (collectively, the “Applicable Laws”), except for such non-compliance as would not, individually or in the aggregate, have a Material Adverse Effect; (ii) have not received any notice from any court or arbitrator or governmental or regulatory authority or third party alleging or asserting non-compliance with any Applicable Laws or any licenses, exemptions, certificates, approvals, clearances, authorizations, permits, registrations and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except for such non-compliance as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) possess all material Authorizations and such Authorizations are valid and in full force and effect and are not in violation of any term of any such Authorizations, except for such violations as would not, individually or in the aggregate, have a Material Adverse Effect; (iv) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Applicable

Pre-Clinical and Clinical Studies. The nonclinical studies and clinical trials conducted by or on behalf of or sponsored by the Company or the Subsidiary, or in which the Company or the Subsidiary have participated, that are described in the Disclosure Materials or the results of which are referred to in the Disclosure Materials, as applicable, and are intended to be submitted to Regulatory Authorities (as defined below) as a basis for product approval, were and, if still pending, are being conducted in all material respects in accordance with standard medical and scientific research procedures and all applicable statutes, rules and regulations of the U.S. Food and Drug Administration (“FDA”) and comparable drug regulatory agencies outside of the United States (including the Agence Nationale de Securité et du Médicament) to which they are subject (collectively, the “Regulatory Authorities”), including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312, and Good Clinical Practices and Good Laboratory Practices; the descriptions in the Disclosure Materials of the results of such studies, tests and trials are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; the Company has no knowledge of any other trials the results of which are inconsistent with or otherwise call into question the results described or referred to in the Disclosure Materials; the Company and the Subsidiary have operated and are currently in compliance in all material respects with all applicable statutes, rules and regulations of the Regulatory Authorities; neither the Company nor the Subsidiary have received any written notices, correspondence or other communication from the Regulatory Authorities or any other governmental agency which could lead to the termination or suspension of any

Title to Property. Each of the Company and the Subsidiary owns or leases all such properties as are necessary to the conduct of its operations as presently conducted in all material respects.

Possession of Intellectual Property. The Company and the Subsidiary own, possess, license or have other rights to use all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual property (collectively, the “Intellectual Property”) necessary for the conduct of the Company’s business as now conducted or as proposed to be conducted in the Disclosure Materials. Except as set forth in the Disclosure Materials, (i) there are no rights of third parties to any such Intellectual Property, except any rights which have not had and are not reasonably likely to result in a Material Adverse Effect; (ii) to the Company’s knowledge, there is no material infringement by third parties of any such Intellectual Property; (iii) there is no

Environmental Laws. The Company and the Subsidiary are (i) in compliance in all material respects with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received and are in compliance in all material respects with all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) have not received notice of any actual or potential liability under any Environmental Law, except where such non-compliance with Environmental Laws, failure to receive required permits, licenses or other approvals, or liability would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect, except as set forth in or contemplated in the Disclosure Materials. Except as set forth in the Disclosure Materials, neither the Company nor the Subsidiary have been named as a “potentially responsible party” under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended.

Accounting Controls and Disclosure Controls. The Company and its consolidated subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Such internal controls over financial reporting are effective at the reasonable assurance level and the Company is not aware of any material weakness in internal controls over financial reporting. The Company and its consolidated subsidiaries maintain “disclosure controls and procedures” (as such term is defined in Rule 13a-15(e) under the Exchange Act); such disclosure controls and procedures are effective at the reasonable assurance level.

Compliance with the Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including Section 402 relating to loans and Sections 302 and 906 relating to certifications.

Payment of Taxes. The Company has filed all tax returns that are required to be filed or has requested extensions thereof (except in any case in which the failure so to file would not have a Material Adverse Effect or except as set forth in or contemplated in the Disclosure Materials) and has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such assessment, fine or penalty that is currently being contested in good faith or as would not have a Material Adverse Effect or except as set forth in or contemplated in the Disclosure Materials.

Insurance. The Company and the Subsidiary are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which they are engaged; all policies of insurance and fidelity or surety bonds insuring the Company or the Subsidiary or its respective businesses, assets, employees, officers and directors are in full force and effect; the Company and the Subsidiary are in compliance with the terms of such policies and instruments in all material respects; and there are no claims by the Company or the Subsidiary under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; neither the Company nor the Subsidiary has been refused any insurance coverage sought or applied for; and

ERISA Compliance. To the knowledge of the Company and the Subsidiary, none of the following events has occurred or exists: (i) a failure to fulfill the obligations, if any, under the minimum funding standards of Section 302 of the United States Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and the regulations and published interpretations thereunder with respect to a Plan (as defined below), determined without regard to any waiver of such obligations or extension of any amortization period; (ii) an audit or investigation by the U.S. Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other U.S. federal or state governmental agency or any foreign regulatory agency with respect to the employment or compensation of employees by any of the Company or the Subsidiary that would reasonably be expected to have a Material Adverse Effect; (iii) any breach of any contractual obligation, or any violation of U.S. federal law or applicable qualification standards, with respect to the employment or compensation of employees by the Company or the Subsidiary that would reasonably be expected to have a Material Adverse Effect. None of the following events has occurred or, to the knowledge of the Company and the Subsidiary, is reasonably likely to occur: (i) a material increase in the aggregate amount of contributions required to be made to all Plans in the current fiscal year of the Company and the Subsidiary compared to the amount of such contributions made in the most recently completed fiscal year of the Company and the Subsidiary; (ii) a material increase in the “accumulated post-retirement benefit obligations” (within the meaning of Statement of Financial Accounting Standards 106) of the Company and the Subsidiary compared to the amount of such obligations in the most recently completed fiscal year of the Company and the Subsidiary; (iii) any event or condition giving rise to a liability under Title IV of ERISA that would reasonably be expected to have a Material Adverse Effect; or (iv) the filing of a claim by one or more employees or former employees of the Company or the Subsidiary related to their employment that would reasonably be expected to have a Material Adverse Effect. For purposes of this paragraph, the term “Plan” means a plan (within the meaning of Section 3(3) of ERISA) subject to Title IV of ERISA with respect to which the Company or the Subsidiary may have any liability.

Brokers. Except as otherwise disclosed in the engagement letters entered into by and among the Company and the Placement Agents, and the Company and the Advisor, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

Investment Company Act. The Company is not, and after giving effect to the transactions contemplated by this Agreement, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended.

Absence of Manipulation. Neither the Company nor the Subsidiary have taken, directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or European Union and French laws, stabilization or manipulation of the price of the shares or any security of the Company to facilitate the sale or resale of the shares of the Company.

No Market Abuse. The Company has complied and complies with any and all applicable rules relating to market abuse (including insider trading) and has taken adequate measures and has adequate procedures in place in order to ensure such compliance, and the sale of the [ABSAs]/[PFW-BS-PFWs] and the consummation of the transactions contemplated by this Agreement will not constitute a violation by the Company of any applicable “insider dealing,” “insider trading” or similar legislation, and no person acting on its behalf has done any act or engaged in any course of conduct constituting such violation.

Related-Party Transactions. There are no business relationships or related-party transactions, including conventions réglementées under Article L. 225-38 et seq. of the French Commercial Code, involving the Company or any of its subsidiaries or any other person required to be described in the Disclosure Materials that have not been described as required. All related party transactions described therein have been duly authorized and executed by the Company or one of its subsidiaries, as the case may be. Neither the Company nor any of its subsidiaries is engaged in any material transaction with their respective directors, officers, management shareholders or any other person, including persons formerly holding such positions, on terms that are not available from or to other parties on an arm’s-length basis.

No Unlawful Payments. Neither the Company nor the Subsidiary nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or the Subsidiary is aware of or has taken any action, directly or indirectly, that would reasonably be expected to result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, the rules

Compliance with Anti-Money Laundering Laws. The operations of the Company and the Subsidiary are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements and the money laundering statutes and the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or the Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

No Conflicts with Sanctions Laws. Neither the Company nor the Subsidiary nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or the Subsidiary (i) is currently the subject of any sanctions administered or imposed by the United States (including any administered or enforced by the Office of Foreign Assets Control of the U.S. Treasury Department, the U.S. Department of State, or the Bureau of Industry and Security of the U.S. Department of Commerce), the United Nations Security Council, the European Union, the United Kingdom (including sanctions administered or controlled by His Majesty’s Treasury) or France (including sanctions administered or controlled by the French Treasury) (collectively, “Sanctions” and such persons, “Sanctioned Persons”) or (ii) will, directly or indirectly, use the proceeds of the offering and sale of the [ABSAs]/[PFW-BS-

Lending Relationship. Except as disclosed in the Disclosure Materials, the Company (i) does not have any material lending or other relationship with any bank or lending affiliate of the Placement Agents or the Advisor and (ii) does not intend to use any of the proceeds from the sale of the [ABSAs]/[PFW-BS-PFWs] to repay any outstanding debt owed to any affiliate of the Placement Agents or the Advisor.

No Immunity. Neither the Company nor the Subsidiary nor any of their properties or assets has any immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution or otherwise).

No Marketing Approval. None of the Company’s product candidates have received marketing approval from any Regulatory Authority.

Cybersecurity. Except as disclosed in the Disclosure Materials, (x) to the Company’s knowledge, there has been no material security breach or other material compromise of or relating to any of the Company’s or the Subsidiary’s information technology and computer systems, networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third-party data maintained by or on behalf of them), equipment or technology (collectively, “IT Systems and Data”) and (y) the Company and the Subsidiary have not been notified of, and have no knowledge of any event or condition that would reasonably be expected to result in, any material security breach or other material compromise to their IT Systems and Data; (ii) the Company and the Subsidiary have taken all commercially reasonable measures to comply with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data, or to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, in the case of this clause (ii), individually or in the aggregate, be reasonably expected to have a Material Adverse Effect; and (iii) the Company has implemented backup and disaster recovery technology consistent with generally accepted industry standards and practices for companies of a similar size and stage of development.

Privacy. The Company and the Subsidiary are, and at all times have been, in compliance with all applicable data privacy and security laws and regulations, including Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (collectively, the “Privacy Laws”), except for such non-compliance as would not, individually or in the aggregate, have a Material Adverse Effect. The Company and the Subsidiary have at all times made all material disclosures to users or customers required by Privacy Laws, and such disclosures have been accurate in all material respects and not in violation of any Privacy Law. To the knowledge of the Company, the execution, delivery and performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach or violation of any Privacy Laws. The Company and the Subsidiary (i) have not received written notice from any governmental authority of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, (ii) are not currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law, and (iii) are not a party to any order or decree that imposes any obligation or liability under any Privacy Law.

Stock Exchange Listing. The Company’s ordinary shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and the ADSs are listed on the Nasdaq or such other national securities exchange on which the ADSs are then listed (the “Principal Market”), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the ordinary shares under the Exchange Act or delisting the ADSs from the Principal Market, nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration or listing. To the Company’s knowledge, it is in compliance with all applicable listing requirements of the Principal Market and of Euronext. The ordinary shares are currently eligible for electronic transfer through the DTC or another established clearing corporation and the Company is current in payment of the fees to the DTC (or such other established clearing corporation) in connection with such electronic transfer.

No Unlawful Contributions or Other Payments. Neither the Company nor the Subsidiary nor, to the best of the Company’s knowledge, any employee or agent of the Company or the Subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Disclosure Materials.

Duties, Transfer Taxes, Etc. No transaction, stamp, documentary, capital, issuance, registration, transfer, (including, for the avoidance of doubt, financial transaction tax as set out in Article 235 ter ZD of the French Tax Code) are payable by or on behalf of the Placement Agents or the Advisor, the Company or the Subsidiary in France or to any taxing authority thereof or therein in connection with (i) the issuance, sale and delivery of the [ABSAs]/[PFW-BS-PFWs] by the Company; (ii) the transfer of the [ABSAs]/[PFW-BS-PFWs] by the Placement Agents or the Advisor; or (iii) the execution, delivery and performance of this Agreement or any other document to be furnished hereunder.

Private Placement. Assuming the accuracy of the Subscriber’s representations and warranties set forth in Section 4.1, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Subscriber as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal Market.

No General Solicitation. Neither the Company nor any person acting on behalf of the Company (including the Placement Agents and the Advisor) has offered or sold any of the Securities by any form of general solicitation or general advertising.

PFIC Reporting. Following the Closing Date, the Company shall make an annual determination whether the Company will be classified as a “passive foreign investment company” within the meaning of Section 1297 of the Internal Revenue Code (a “PFIC”) and promptly inform the Subscriber of such determination, provided that each Subscriber will be deemed to be so informed pursuant to this Section if the Company includes such determination on its website or in its Annual Report on Form 10-K or other public filing with the Commission. The Company shall promptly provide to the Subscriber any information that the Subscriber reasonably request in order for the Subscriber to (i) verify the determinations made pursuant to this Section in connection with an audit or otherwise, (ii) comply with their federal, state, or local tax return filing and information reporting obligations and (iii) make and maintain a “qualified electing fund” election (as defined in the Internal Revenue Code) with respect to the Company as a result of the Company being classified as a PFIC, provided that the Company may provide such information on its website.

Interpretation

Exercise

Exercise Period

Exercise Price

Terms of exercise

Confirmation of Exercise

Issue of ABSA Warrant Shares Upon Exercise

ABSA Warrant Shares

Form of ABSA Warrant Shares

Dividend Due Date and Rights Attached to the ABSA Warrant Shares

Transfer of ABSA Warrant Shares

Fractional Interests

Adjustments of the Exercise Ratio

Adjustments to the Exercise Ratio

financial transactions (issuance of Shares or any other securities of any nature) with listed preferential subscription rights or by free allocation of listed subscription warrants;

free allocation of Shares to shareholders, regrouping or splitting Shares;

incorporation of reserves, profits or premiums into equity, by increasing the nominal value of the Shares;

distribution of reserves and of any Share premium, in cash or in kind;

free allocation, to the shareholders of the Company of any securities of the Company (except Shares);

merger by acquisition (fusion par absorption), merger (fusion par création d’une nouvelle société), spin-off, or division (scission) of the Company;

buyback of its own Shares at a price higher than the Trading Market price;

amortization of the share capital; and

change in the allocation of profits and/or creation of preferred Shares;

For financial transactions (issuance of Shares or any other securities of any nature) with listed preferential right to subscription, the new Exercise Ratio will be determined by the Calculation Agent and will equal the product of the Exercise Ratio applicable before the start of the Transaction at issue and the following ratio: